ReviewArchives of disease in childhood2023
Graves' disease: moving forwards.
Review in Archives of disease in childhood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Likelihood of Laryngeal Involvement in Autoimmune Thyroid Disorder Patients: A Meta-Analysis.Endocrine, metabolic & immune disorders drug targets · 2025Pooled it
- The Cross-Knit Between Immune Cells and Thyroid Function in Autoimmune Thyroid Disorders: What We Can Learn from Inborn Errors of Immunity.Children (Basel, Switzerland) · 2026Review
- Abnormal Elevation of the Expression of Costimulatory Molecule CD226 in Graves' DiseaseEndocrine, metabolic & immune disorders drug targets · 2026Article
- Graves' disease and autoimmune hepatitis overlap syndrome with coincidental simultaneous presentation in a pediatric patient.Pediatric endocrinology, diabetes, and metabolism · 2026Article
- Hub genes and key pathways of Graves' disease: bioinformatics analysis and validation.Hormones (Athens, Greece) · 2025Article
- Sex-Related Differences in Risk Factors Associated With Nonhealing or Recurrence of Hyperthyroidism in Patients With Graves' Disease Treated With Radioactive Iodine.Health care science · 2025Article
- Interpreting the Function of the IL-23/IL-17 Axis through Bioinformatics.Endocrine, metabolic & immune disorders drug targets · 2025Review
- A Systematic Review of Patient Preferences, Expectations, and Values for the Management and Treatment of Graves Disease.Patient preference and adherence · 2025Review
- Th17-associated cytokine gene hypomethylation reflects epigenetic dysregulation in graves' disease.Frontiers in immunology · 2025Article
- The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.Pharmaceutics · 2024Review
- Once upon a time in Anatolia: the kings with bulging eyes.Hormones (Athens, Greece) · 2024Review
- Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study.Journal of translational medicine · 2024Article
- Updates in the Management of Graves Disease in Children.Ewha medical journal · 2023Review
- Different doses of methimazole treatment of children and adolescents with graves' disease: a clinical study based on 161 cases of outpatients.BMC endocrine disorders · 2023Article
- [Adverse reactions of methimazole in children with hyperthyroidism].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Mild Thyrotoxicosis due to Seronegative Graves' Disease or Disseminated Thyroid Autonomy.AACE clinical case reportsArticle
- Clinical Characteristics and Surgical Outcomes of Paediatric Thyroid Disorders in a Nigerian Mission Hospital: A Nine-Year Review.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Graves' disease is a rare disorder that continues to present clinicians and families with a series of challenges. There are no new established treatments for children or adolescents, but the outcomes of recent clinical trials and meta-analyses have helped clinicians to prepare families for the road ahead. We have a more refined understanding of how to administer antithyroid drugs, which one to use and how long to treat the young person. We also have a greater insight into how best to reduce any risks associated with surgery and radioiodine. We understand more about long-term outcomes and their determinants and have greater awareness about the impact of the disease and its treatment on quality of life. A holistic approach to management is key to supporting and counselling young people and their families about the diagnosis and management options. In this review, we will discuss the recent literature and reflect on how this should be translated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.